{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T10:49:42Z","timestamp":1770547782179,"version":"3.49.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,8,23]],"date-time":"2015-08-23T00:00:00Z","timestamp":1440288000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Tumor Biol."],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s13277-015-3947-4","type":"journal-article","created":{"date-parts":[[2015,8,22]],"date-time":"2015-08-22T04:09:30Z","timestamp":1440216570000},"page":"1573-1579","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Ruxolitinib induces autophagy in chronic myeloid leukemia cells"],"prefix":"10.1007","volume":"37","author":[{"given":"Bakiye Goker","family":"Bagca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozgun","family":"Ozalp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cansu Caliskan","family":"Kurt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeynep","family":"Mutlu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guray","family":"Saydam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cumhur","family":"Gunduz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cigir Biray","family":"Avci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,23]]},"reference":[{"key":"3947_CR1","doi-asserted-by":"crossref","unstructured":"Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002; 2292-2302.","DOI":"10.1182\/blood-2002-04-1199"},{"key":"3947_CR2","first-page":"937","volume":"2009","author":"JW Vardiman","year":"2008","unstructured":"Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2008;2009:937\u201351.","journal-title":"Blood"},{"issue":"5","key":"3947_CR3","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/ajh.23691","volume":"89","author":"E Jabbour","year":"2014","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am J Hematol. 2014;89(5):547\u201356.","journal-title":"Am J Hematol"},{"key":"3947_CR4","unstructured":"Nowell P, Hungerford D. A minute chromosome in human chronic granulocytic leukemia [abstract]. Science. 1960;132:1497."},{"key":"3947_CR5","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290\u20133.","journal-title":"Nature"},{"key":"3947_CR6","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/315550a0","volume":"315","author":"E Shtivelman","year":"1985","unstructured":"Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 1985;315:550\u20134.","journal-title":"Nature"},{"key":"3947_CR7","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1056\/NEJMra044389","volume":"353","author":"DS Krause","year":"2005","unstructured":"Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005;353:172\u201387.","journal-title":"N Engl J Med"},{"key":"3947_CR8","first-page":"100","volume":"56","author":"E Buchdunger","year":"1996","unstructured":"Buchdunger E. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996;56:100\u20134.","journal-title":"Cancer Res"},{"key":"3947_CR9","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","volume":"99","author":"CL Sawyers","year":"2002","unstructured":"Sawyers CL. Imatinib induces hematologic hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99:3530\u20139.","journal-title":"Blood"},{"key":"3947_CR10","doi-asserted-by":"crossref","unstructured":"Manley P, Cowan-Jacob S, Mestan J. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochimica et Biophysica Acta. 2005;1754.","DOI":"10.1016\/j.bbapap.2005.07.040"},{"key":"3947_CR11","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2147\/CE.S6003","volume":"4","author":"E Jabbour","year":"2009","unstructured":"Jabbour E, Cortes J, Kantarjian H. Nilotinib for the treatment of chronic myeloid leukemia: an evidence-based review. Core Evid. 2009;4:207\u201313.","journal-title":"Core Evid"},{"issue":"11","key":"3947_CR12","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","volume":"66","author":"JS Okarski","year":"2006","unstructured":"Okarski JS, Newitt JA, Chang CY, Cheng JD, Wittekind M, Kiefer SE, et al. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 2006;66(11):5790\u20137.","journal-title":"Cancer Res"},{"issue":"5","key":"3947_CR13","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"T O'Hare","year":"2009","unstructured":"O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16(5):401\u201312.","journal-title":"Cancer Cell"},{"key":"3947_CR14","doi-asserted-by":"crossref","unstructured":"\u00c1valos Y, Canales J, Bravo-Sagua R, Criollo A, Lavandero S, Quest AFG. Tumor suppression and promotion by autophagy. BioMed Res Int. 2014;1-15.","DOI":"10.1155\/2014\/603980"},{"key":"3947_CR15","doi-asserted-by":"crossref","first-page":"15260","DOI":"10.3390\/ijms140815260","volume":"14","author":"E Strozyk","year":"2013","unstructured":"Strozyk E, Kulms D. The role of AKT\/mTOR pathway in stress response to UV-irradiation: implication in skin carcinogenesis by regulation of apoptosis, autophagy and senescence. Int J Mol Sci. 2013;14:15260\u201385.","journal-title":"Int J Mol Sci"},{"key":"3947_CR16","doi-asserted-by":"crossref","unstructured":"Fan YJ, Zong WX. The cellular decision between apoptosis and autophagy. Chin J Cancer.2013; 121-29.","DOI":"10.5732\/cjc.012.10106"},{"issue":"9","key":"3947_CR17","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2217\/fon.11.81","volume":"7","author":"A Ostojic","year":"2011","unstructured":"Ostojic A, Vrhovac R, Verstovsek S. Ruxolitinib: a new JAK1\/2 inhibitor that offers promising options for treatment of myelofibrosis. Future Oncol. 2011;7(9):1035\u201343.","journal-title":"Future Oncol"},{"key":"3947_CR18","first-page":"1","volume":"e22925","author":"CS Nicolas","year":"2013","unstructured":"Nicolas CS, Amici M, Bortolotto ZA, Doherty A, Csaba Z, Fafouri A, et al. The role of JAK-STAT signaling within the CNS. Landes Biosci. 2013;e22925:1\u201310.","journal-title":"Landes Biosci"},{"issue":"5143","key":"3947_CR19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1126\/science.8272872","volume":"263","author":"C L\u00fctticken","year":"1994","unstructured":"L\u00fctticken C, Wegenka UM, Yuan J, Buschmann J, Schindler C, Ziemiecki A, et al. Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science. 1994;263(5143):89\u201392.","journal-title":"Science"},{"issue":"16","key":"3947_CR20","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.2165\/11209340-000000000-00000","volume":"72","author":"LPH Yang","year":"2012","unstructured":"Yang LPH, Keating GM. Ruxolitinib in the treatment of myelofibrosis. Drugs. 2012;72(16):2117\u201327.","journal-title":"Drugs"},{"key":"3947_CR21","unstructured":"Ruxolitinib, Pan JAK Inhibitor www.invivogen.com\/inhibitors"},{"issue":"4","key":"3947_CR22","first-page":"435","volume":"11","author":"M Bahadori","year":"2006","unstructured":"Bahadori M. New advances in RNAs. Arch Iran Med. 2006;11(4):435\u201343.","journal-title":"Arch Iran Med"},{"issue":"9","key":"3947_CR23","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1021\/ol900350k","volume":"11","author":"Q Lin","year":"2009","unstructured":"Lin Q, Meloni D, Pan Y, Xia M, Rodgers J, Shepard S, et al. Enantioselective synthesis of Janus kinase inhibitor INCB018424 via an organocatalytic aza-Michael reaction. Org Lett. 2009;11(9):1999\u20132002.","journal-title":"Org Lett"},{"key":"3947_CR24","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","volume":"115","author":"A Quint\u00e1s-Cardama","year":"2010","unstructured":"Quint\u00e1s-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA. Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115:3109\u201317.","journal-title":"Blood"},{"issue":"1-2","key":"3947_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-1119(02)00398-0","volume":"285","author":"T Kisseleva","year":"2002","unstructured":"Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW. Signaling through the JAK\/STAT pathway, recent advances and future challenges. Gene. 2002;285(1-2):1\u201324.","journal-title":"Gene"},{"issue":"12","key":"3947_CR26","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1002\/art.37691","volume":"64","author":"A Yarilina","year":"2012","unstructured":"Yarilina A, Xu K, Chan C, Ivashkiv LB. Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors. Arthritis Rheum. 2012;64(12):3856\u201366.","journal-title":"Arthritis Rheum"},{"issue":"19","key":"3947_CR27","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1182\/blood-2013-02-485607","volume":"122","author":"P Gallipoli","year":"2013","unstructured":"Gallipoli P, Pellicano F, Morrison H, Laidlaw K, Allan EK, Bhatia R, et al. Autocrine TNF-\u03b1 production supports CML stem and progenitor cell survival and enhances their proliferation. Blood. 2013;122(19):3335\u20139.","journal-title":"Blood"},{"issue":"9","key":"3947_CR28","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.bcp.2006.07.003","volume":"72","author":"A Wullaert","year":"2006","unstructured":"Wullaert A, Heyninck K, Beyaert R. Mechanisms of crosstalk between TNF-induced NFkappaB and JNK activation in hepatocytes. Biochem Pharmacol. 2006;72(9):1090\u2013101.","journal-title":"Biochem Pharmacol"},{"issue":"45","key":"3947_CR29","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1038\/onc.2011.156","volume":"30","author":"SJ Stein","year":"2011","unstructured":"Stein SJ, Baldwin AS. NF-\u03baB suppresses ROS levels in BCR-ABL(+) cells to prevent activation of JNK and cell death. Oncogene. 2011;30(45):4557\u201366.","journal-title":"Oncogene"},{"issue":"2","key":"3947_CR30","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.canlet.2013.08.009","volume":"341","author":"GS Wilson","year":"2013","unstructured":"Wilson GS, Tian A, Hebbard L, Duan W, George J, Li X, et al. Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitro. Cancer Lett. 2013;341(2):224\u201330.","journal-title":"Cancer Lett"},{"issue":"11","key":"3947_CR31","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s10495-014-1030-z","volume":"19","author":"Y Hu","year":"2014","unstructured":"Hu Y, Hong Y, Xu Y, Liu P, Guo DH, Chen Y. Inhibition of the JAK\/STAT pathway with ruxolitinib overcomes cisplatin resistance in non-small-cell lung cancer NSCLC. Apoptosis. 2014;19(11):1627\u201336.","journal-title":"Apoptosis"},{"issue":"21","key":"3947_CR32","doi-asserted-by":"crossref","first-page":"5766","DOI":"10.1093\/emboj\/cdf562","volume":"21","author":"A Klejman","year":"2002","unstructured":"Klejman A, Schreiner SJ, Nieborowska-Skorska M, Slupianek A, Wilson M, Smithgall TE, et al. The Src family kinase Hck couples BCR\/ABL to STAT5 activation in myeloid leukemia cells. EMBO J. 2002;21(21):5766\u201374.","journal-title":"EMBO J"},{"issue":"7","key":"3947_CR33","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/ng.389","volume":"41","author":"Y Chen","year":"2009","unstructured":"Chen Y, Hu Y, Zhang H, Peng C, Li S. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat Genet. 2009;41(7):783\u201392.","journal-title":"Nat Genet"},{"issue":"1","key":"3947_CR34","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1021\/mp300405n","volume":"10","author":"DW Woessner","year":"2013","unstructured":"Woessner DW, Lim CS. Disrupting BCR-ABL in combination with secondary leukemia specific pathways in CML cells leads to enhanced apoptosis and decreased proliferation. Mol Pharm. 2013;10(1):270\u20137.","journal-title":"Mol Pharm"},{"issue":"7","key":"3947_CR35","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","volume":"351","author":"CH Jamieson","year":"2004","unstructured":"Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, et al. Granulocytemacrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004;351(7):657\u201367.","journal-title":"N Engl J Med"},{"issue":"1","key":"3947_CR36","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/ng791","volume":"30","author":"D Perrotti","year":"2002","unstructured":"Perrotti D, Cesi V, Trotta R, Guerzoni C, Santilli G, Campbell K, et al. BCR-ABL suppresses C\/EBPalpha expression through inhibitory action of hnRNP E2. Nat Genet. 2002;30(1):48\u201358.","journal-title":"Nat Genet"},{"issue":"4","key":"3947_CR37","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1084\/jem.20122727","volume":"211","author":"LM Treanor","year":"2014","unstructured":"Treanor LM, Zhou S, Janke L, Churchman ML, Ma Z, Lu T, et al. Interleukin-7 receptor mutants initiate early T cell precursor leukemia in murine thymocyte progenitors with multipotent potential. J Exp Med. 2014;211(4):701\u201313.","journal-title":"J Exp Med"},{"issue":"6","key":"3947_CR38","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nm1579","volume":"13","author":"SE Mullican","year":"2007","unstructured":"Mullican SE, Zhang S, Konopleva M, Ruvolo V, Andreeff M, Milbrandt J, et al. Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia. Nat Med. 2007;13(6):730\u20135.","journal-title":"Nat Med"},{"key":"3947_CR39","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ccr.2007.10.015","volume":"12","author":"EK Thomas","year":"2007","unstructured":"Thomas EK, Cancelas JA, Chae HD. Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease. Cancer Cell. 2007;12:467\u201378.","journal-title":"Cancer Cell"},{"issue":"8","key":"3947_CR40","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/ng.2350","volume":"44","author":"H Zhang","year":"2012","unstructured":"Zhang H, Peng C, Hu Y, Li H, Sheng Z, Chen Y, et al. The Blk pathway functions as a tumor suppressor in chronic myeloid leukemia stem cells. Nat Genet. 2012;44(8):861\u201371.","journal-title":"Nat Genet"},{"issue":"5","key":"3947_CR41","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/leu.2011.360","volume":"26","author":"E Weisberg","year":"2012","unstructured":"Weisberg E, Azab AK, Manley PW, Kung AL, Christie AL, Bronson R, et al. Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib. Leukemia. 2012;26(5):985\u201390.","journal-title":"Leukemia"},{"issue":"5","key":"3947_CR42","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1182\/blood-2008-03-143644","volume":"112","author":"R Rao","year":"2008","unstructured":"Rao R, Fiskus W, Yang Y, Lee P, Joshi R, Fernandez P, et al. HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood. 2008;112(5):1886\u201393.","journal-title":"Blood"},{"issue":"11","key":"3947_CR43","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/nm.3364","volume":"19","author":"DS Krause","year":"2013","unstructured":"Krause DS, Fulzele K, Catic A, Sun CC, Dombkowski D, Hurley MP, et al. Differential regulation of myeloid leukemias by the bone marrow microenvironment. Nat Med. 2013;19(11):1513\u20137.","journal-title":"Nat Med"},{"key":"3947_CR44","author":"EA Dunlop","year":"2014","unstructured":"Dunlop EA, Tee AR. mTOR and autophagy: a dynamic relationship governed by nutrients and energy. Semin Cell Dev Biol. 2014. doi: 10.1016\/j.semcdb.2014.08.006 .","journal-title":"Semin Cell Dev Biol"},{"issue":"3","key":"3947_CR45","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/jcp.22407","volume":"226","author":"C Evangelisti","year":"2011","unstructured":"Evangelisti C, Ricci F, Tazzari P, Chiarini F, Battistelli M, Falcieri E, et al. Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia. J Cell Physiol. 2011;226(3):822\u201331.","journal-title":"J Cell Physiol"},{"issue":"23","key":"3947_CR46","doi-asserted-by":"crossref","first-page":"9763","DOI":"10.1007\/s00253-014-6003-1","volume":"98","author":"J Fan","year":"2014","unstructured":"Fan J, Dong X, Zhang W, Zeng X, Li Y, Sun Y, et al. Tyrosine kinase inhibitor Thiotanib targets Bcr-Abl and induces apoptosis and autophagy in human chronic myeloid leukemia cells. Appl Microbiol Biotechnol. 2014;98(23):9763\u201375.","journal-title":"Appl Microbiol Biotechnol"},{"issue":"Suppl 2","key":"3947_CR47","doi-asserted-by":"crossref","first-page":"S307","DOI":"10.1016\/j.clml.2013.07.011","volume":"13","author":"N Bartalucci","year":"2013","unstructured":"Bartalucci N, Guglielmelli P, Vannucchi AM. Rationale for targeting the PI3K\/Akt\/mTOR pathway in myeloproliferative neoplasms. Clin Lymphoma Myeloma Leuk. 2013;13 Suppl 2:S307\u20139.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"46","key":"3947_CR48","doi-asserted-by":"crossref","first-page":"5359","DOI":"10.1038\/onc.2013.40","volume":"32","author":"AB Lee-Sherick","year":"2013","unstructured":"Lee-Sherick AB, Eisenman KM, Sather S, McGranahan A, Armistead PM, McGary CS, et al. Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia. Oncogene. 2013;32(46):5359\u201368.","journal-title":"Oncogene"},{"issue":"7","key":"3947_CR49","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1038\/sj.cdd.4402149","volume":"14","author":"S Luo","year":"2007","unstructured":"Luo S, Rubinsztein DC. Atg5 and Bcl-2 provide novel insights into the interplay between apoptosis and autophagy. Cell Death Differ. 2007;14(7):1247\u201350.","journal-title":"Cell Death Differ"},{"issue":"8","key":"3947_CR50","doi-asserted-by":"crossref","first-page":"e70442","DOI":"10.1371\/journal.pone.0070442","volume":"8","author":"X Peng","year":"2013","unstructured":"Peng X, Li W, Yuan L, Mehta RG, Kopelovich L, McCormick DL. Inhibition of proliferation and induction of autophagy by atorvastatin in PC3 prostate cancer cells correlate with downregulation of Bcl2 and upregulation of miR-182 and p21. PLoS One. 2013;8(8):e70442.","journal-title":"PLoS One"}],"container-title":["Tumor Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-015-3947-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13277-015-3947-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-015-3947-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T18:20:41Z","timestamp":1567102841000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13277-015-3947-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,23]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["3947"],"URL":"https:\/\/doi.org\/10.1007\/s13277-015-3947-4","relation":{},"ISSN":["1010-4283","1423-0380"],"issn-type":[{"value":"1010-4283","type":"print"},{"value":"1423-0380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,23]]}}}